Insulin‐like growth factor binding protein‐1 in NIDDM: relationship with the insulin resistance syndrome

Mohamed‐Ali, J. H. Pinkney, A. Panahloo, Cwyfan‐Hughes, J. M.P. Holly, J. S. Yudkin

Research output: Contribution to journalArticlepeer-review

Abstract

<jats:sec><jats:title>OBJECTIVE</jats:title><jats:p>In order to examine the role of insulin‐like growth factors in the pathogenesis of accelerated macrovascular disease in noninsulin‐dependent diabetes mellitus (NIDDM), we investigated the relationship between the insulin resistance syndrome and the IGF axis.</jats:p></jats:sec><jats:sec><jats:title>DESIGN</jats:title><jats:p>Cross‐sectional analysis of the relationship between insulin resistance syndrome variables and concentrations of IGF‐1, IGF‐2, IGFBP‐1 and IGFBP‐3 in 80 subjects with NIDDM.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>After correcting for age, sex and body mass index, concentrations of IGFBP‐1, correlated with those of HDL‐cholesterol (<jats:italic>r</jats:italic> = 0.40; <jats:italic>P</jats:italic> &lt; 0.001), triglycerides (<jats:italic>r</jats:italic> = − 0.24; <jats:italic>P</jats:italic> = 0.04), insulin (<jats:italic>r</jats:italic> = − 0.39; <jats:italic>P</jats:italic> &lt; 0.001), intact proinsulin (<jats:italic>r</jats:italic> = − 0.32; <jats:italic>P</jats:italic> = 0.006), des 31,32 proinsulin (<jats:italic>r</jats:italic> = − 0.40; <jats:italic>P</jats:italic> = 0.001), and with insulin sensitivity (<jats:italic>r</jats:italic> = 0.38; <jats:italic>P</jats:italic> = 0.001) and PAI‐1 activity (<jats:italic>r</jats:italic> = − 0.24; <jats:italic>P</jats:italic> = 0.05); IGF‐1 levels only correlated with those of HDL‐cholesterol (<jats:italic>r</jats:italic> = − 0.33; <jats:italic>P</jats:italic> = 0.005), and this was not explained by IGFBP‐1 or insulin sensitivity. With additional correction for insulin, concentrations of IGFBP‐1 still correlated with HDL‐cholesterol (<jats:italic>r</jats:italic> = 0.40; <jats:italic>P</jats:italic> &lt; 0.001), but not those of triglycerides or PAI‐1 activity. There were no significant relationships between levels of IGF‐2 and any of the variables investigated, and IGFBP‐3 levels only correlated with those of total cholesterol (<jats:italic>r</jats:italic> = 0.24, <jats:italic>P</jats:italic> = 0.04).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>In NIDDM, concentrations of IGFBP‐1 are related to those of insulin, insulin sensitivity, serum lipoproteins and PAI‐1 activity. The relationship between concentrations of IGFBP‐1 and HDL‐cholesterol is not explained by insulin. Concentrations of IGF‐1 are linked to HDL‐cholesterol, and this is not explained by levels of IGFBP‐1. IGFBP‐1 concentrations were related to PAI‐1 activity, and this may be explained by insulin, which regulates the production of IGFBP‐1 and PAI‐1.</jats:p></jats:sec>
Original languageEnglish
Pages (from-to)221-228
Number of pages0
JournalClinical Endocrinology
Volume50
Issue number2
DOIs
Publication statusPublished - Feb 1999

Fingerprint

Dive into the research topics of 'Insulin‐like growth factor binding protein‐1 in NIDDM: relationship with the insulin resistance syndrome'. Together they form a unique fingerprint.

Cite this